Hatch-Waxman Amendments, Drug Shortages Lead FDA’s 2025 Legislative Agenda

The FDA’s legislative wish list for FY 2025 includes proposals to protect drug supply resiliency, amend the Hatch-Waxman Act, and exercise greater control over recalls.
Source: Drug Industry Daily

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.